A5015956321- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- Colorectal Cancer Treatments and Studies
- Testicular diseases and treatments
- Inflammatory Biomarkers in Disease Prognosis
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Sarcoma Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Cardiac tumors and thrombi
- Head and Neck Cancer Studies
- Immunotherapy and Immune Responses
- Gallbladder and Bile Duct Disorders
- Urologic and reproductive health conditions
- Genital Health and Disease
- Chronic Lymphocytic Leukemia Research
Marmara University
2022-2025
Maltepe University
2025
Klinikum Lippe
2024
Bielefeld University
2024
Erzurum Regional Training and Research Hospital
2023
Ondokuz Mayıs University
2018-2019
Management of melanoma has changed significantly with the discovery targeted therapies and immune checkpoint inhibitors (ICI). Our aim in study is to determine which treatment alternatives, specifically dabrafenib plus trametinib ICIs, are effective adjuvant therapy as first-line metastatic therapy. This retrospective, multicenter included 120 patients diagnosed stage IIIB-IIID receiving both between 2007 2023. Data on clinicopathologic characteristics, regimens outcomes were collected....
Objective: Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive malignancy with a poor prognosis, for which prognostic factors are being investigated. In this study, we aimed to evaluate the significance of Lung Immune Prognostic Index (LIPI) in ES-SCLC patients. Patients and Methods: Our retrospective study evaluated 60 patients who were followed-up treated between 2014 2022 whose data could be accessed. Demographic characteristics, treatments laboratory parameters (lactate...
Objective: Kaposi sarcoma (KS) presents as a multifocal angioproliferative disease with distinct four subtypes, including classical, AIDS-related(epidemic), endemic, and iatrogenic. The rarity of the clinically different characteristics subtypes have led to insufficient experience in treatment follow-up. Based on this, we aim investigate clinicopathological features options KS patients treated followed up our clinic. Patients Methods: study included 66 diagnosed by histopathological...
Background/Objectives: There is an unmet need to improve outcomes in patients with metastatic Ewing sarcoma (ES). This retrospective, multicenter study aimed evaluate the efficacy and safety of topotecan–cyclophosphamide (TC) regimen adult ES who had previously been treated chemotherapy. Methods: enrolled 75 were at five oncology centers Turkey between 2011 2020. Patients TC regimen, consisting topotecan 0.75 mg/m2/day cyclophosphamide 250 mg/m2/day, given daily for 5 days repeated every 21...
Introduction: CDK 4/6 inhibitors are effectively utilized among patients with hormone-positive, HER-2-negative metastatic breast cancer. The dose reduction for these varies between 35% and 57% across multiple trials. We aim to clarify the characteristics of who had dosage effect this on survival outcomes. Materials Methods: study was designed as a retrospective, multicenter study. Patients received in first-line subsequent treatment settings were grouped based reductions. Progression-free...
We aimed to explore the correlation between anti-hypertensive treatment and survival rates in patients with metastatic non-small cell lung cancer (mNSCLC). In this study, we analyzed antihypertensive 300 mNSCLC. Retrospective. Medical faculty hospital. investigated relationship who were diagnosed also examined histological type, performance status, gender, age type of medication used survival. Survival difference mNSCLC without treatment. Among receiving concomitant treatment, 107 (35.7%)...
CDK4/6 inhibitors have changed the landscape of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (BC) management. It is essential to identify predictive and prognostic factors for efficacy inhibitors. We aimed investigate differences in characteristics outcomes patients receiving first-line according PgR status. This multicenter retrospective study included 351 treated with CDK 4/6 HR-positive/HER2-negative BC. Patients were categorized...
Background and Objectives: ROS1 rearrangement is a rare but targetable alteration in non-small-cell lung cancer (NSCLC), occurring 1–2% of cases. Crizotinib, tyrosine kinase inhibitor, has demonstrated efficacy clinical trials, real-world data remain limited. This study evaluates the safety crizotinib ROS1-rearranged NSCLC patients setting. Materials Methods: multicenter, retrospective research included 43 individuals with advanced/metastatic confirmed rearrangements. Patients were treated...
Background: Osteosarcoma is a rare but aggressive bone malignancy. Despite advances in multimodal therapy, survival remains suboptimal, highlighting the need for prognostic markers to guide treatment. Methods: This study included 162 osteosarcoma patients who received neoadjuvant chemotherapy followed by surgery between January 2009 and March 2024. Patients either double (cisplatin + doxorubicin) or triple (MAP PEI) chemotherapy. Survival analyses were conducted using Kaplan–Meier curves,...
Aim: Muscle-invasive bladder cancer requires systemic treatment due to its high risk of metastasis. However, studies comparing neoadjuvant and adjuvant therapy regimens are currently limited. Our goal in this study was compare the efficacy patients receiving or locally advanced cancer. Material Methods: We retrospectively included 107 from 6 centres who underwent radical cystectomy received perioperative chemotherapy. Patients were divided into 2 categories: (i) chemotherapy (n=54) (ii)...
The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is MONALEESA-7 study, and data palbociclib limited. Data are also limited regarding whose dose was reduced due to neutropenia, most common side effect inhibitors. In our we aimed evaluate ribociclib reduction neutropenia progression-free survival. Our a multicenter, retrospective factors affecting survival...
Abstract Objectives Head and neck cancers (HNCs) represent a significant global health concern due to high morbidity mortality rates. Despite therapeutic advances, the prognosis for advanced or recurrent cases remains challenging. Nivolumab obtained approval metastatic HNC based on Phase III CheckMate 141 trial. This study aimed evaluate real-world outcomes of nivolumab in patients with non-nasopharyngeal HNC. Design In this multicenter retrospective study, we analyzed 124 who received...
The prognosis of patients with advanced HCC can vary widely depending on factors such as the stage cancer, patient's overall health, and treatment regimens. This study aimed to investigate survival outcomes associated in hepatocellular carcinoma (HCC). In this retrospective study, data from 23 medical oncology clinics were analyzed. Progression-free (PFS) (OS) values estimated using Kaplan–Meier method. Prognostic which identified univariate analysis subsequently evaluated a multivariate...
Abstract Purpose Endocrine therapy (ET) in combination with CDK 4/6 inhibitors (CDK 4/6i) is the standard treatment modality for hormone receptor (HR)-positive and HER2-negative metastatic breast cancer (mBC). There uncertainty about prognostic predictive value of HER2-low status whether BC an individual biologic subtype. In this study, we aimed to investigate effect HER2 expression on survival mBC patients treated first-line ET plus 4/6i. Methods This multicenter retrospective study...
Objective To investigate the impact of cumulative cisplatin dose on clinical outcomes in locally advanced cervical cancer patients undergoing definitive chemoradiotherapy. Methods A retrospective analysis was conducted 654 with stage IB3–IVA disease treated Radiotherapy applied as external beam pelvic or without para-aortic radiotherapy and brachytherapy. Concomitant chemotherapy form weekly 3 cisplatin. Data demographics, treatment protocols, dose, adverse effects, survival were collected....
Breast cancer (BC) and lung are the most frequently reported cancers in women men, respectively, terms of both numbers cases deaths. 1 It is estimated that 6%-10% BC present as de novo metastatic at time diagnosis, between 25% 30% experience recurrence. 2 While no definitive cure for breast (MBC) available to date, advent novel systemic therapies has enhanced survival outcomes patients with this condition.
Trastuzumab deruxtecan (T-DXd) is a novel anti-HER2 antibody-drug conjugate formed by the combination of trastuzumab and deruxtecan. It used in human epidermal growth factor 2 receptor (HER2) mutant breast, stomach colorectal cancers as well non-small cell lung cancer (NSCLC). The 58-year-old denovo metastatic NSCLC patient we will discuss here progressed with newly developing brain metastasis under first-line carboplatin/paclitaxel treatment. After next generation sequencing revealed...
In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate effectiveness safety of as third-line patients with who progressed while taking bevacizumab-based therapy. retrospective, multicenter Turkey included 65 treated between 2021 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase...
Objective: The systemic inflammatory response (SIR) is known as an important factor associated with tumorigenesis and tumor progression, can be reflected by markers. One of the markers that reflect this lung immune prognostic index (LIPI). It based on a derived neutrophil-to-lymphocyte ratio (dNLR) lactate dehydrogenase (LDH) level. We aimed to investigate significance LIPI in locally advanced rectal cancer (LARC) patients treated neoadjuvant chemoradiotherapy (NACRT). Methods: In...
This study aims to evaluate whether sarcopenia, measured by chest computed tomography (CT), affects survival outcomes and postoperative complications in soft tissue sarcoma (STS) patients undergoing surgery. In this retrospective study, CT scans of 79 were reviewed measure pectoralis T12 vertebra muscle area. Both then adjusted for height (cm2/m2) as index (PMI) (TMI). Analyses performed dichotomizing indices at gender-specific 50th percentile; PMI TMI < percentile defined low, ≥50th high....
Nasopharyngeal carcinoma (NPC) accounts for 0.01% of all carcinomas, and 70% patients have locally advanced disease with a poor prognosis. The mainstay therapy is chemoradiotherapy (CRT), concurrent administration platinum-based agents irradiation provides high local control rates. However, induction (neoadjuvant) chemotherapy (ICT) prior to CRT recommended large tumors tumor burden at the category 1 level. For ICT, doublet or triplet combination regimens are recommended. Selected time...
Many developing countries lack access to recommended first-line treatments for metastatic renal cell carcinoma (mRCC), such as immune checkpoint inhibitors (ICIs) or ICI-tyrosine kinase inhibitor (TKI) combinations. As a result, predictive markers are necessary identify patients who may benefit from single-agent TKIs long-term response. This study aims parameters. was multi-centre, retrospective of with mRCC were undergoing treatment sunitinib pazopanib. Patients had been diagnosed and not...
Total neoadjuvant therapy (TNT) has emerged as a promising approach for managing locally advanced rectal cancer (LARC), aiming to enhance resectability, increase pathological complete response (pCR), improve treatment compliance, survival, and sphincter preservation. This study compares the clinical outcomes of TNT, with either induction or consolidation chemotherapy, those standard chemoradiotherapy (CRT). In this retrospective multi-institutional study, patients stage II-III LARC who...
Background: Distant metastases in serous borderline ovarian tumors (sBOT) are rare. Accounting for only 1% of all sBOT. This includes spread to supradiaphragmatic lymph nodes, particularly the cardiophrenic nodes (CPLK). Since complete resection is an established prognostic factor and determinate risk recurrent disease, this unusual manifestation poses significant challenges diagnosis. Highlighting complexities involved treatment decision-making prognosis assessment such cases.